Is Broach Lifecare overvalued or undervalued?

As of 8 October 2025, the valuation grade for Broach Lifecare has moved from attractive to very attractive. Based on the analysis, the company appears to be undervalued. Key ratios include a PE Ratio of 10.35, an EV to EBIT of 11.20, and a ROCE of 6.90%.
In comparison to its peers, Broach Lifecare's PE Ratio is significantly lower than Apollo Hospitals at 70.05 and Max Healthcare at 92.31, both of which are categorized as very expensive. The PEG Ratio for Broach Lifecare stands at 0.00, indicating potential growth at a low price, further supporting the undervaluation thesis. Additionally, Broach Lifecare's recent stock performance has lagged behind the Sensex, with a year-to-date return of -21.06% compared to the Sensex's 4.65%, reinforcing the notion that the stock may be undervalued in the current market environment.